Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Genome Medicine
|
November 4, 2025
Genome instability and crosstalk with the immune response
Roman M Chabanon, François-Xavier Danlos, Kaissa Ouali, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2024
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
Laurent Mathiot, David Combarel, Justin Cagnat, et al.
Cancer
|
June 2, 2024
Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer
Félix Blanc-Durand, Geraldine M Camilleri, Arnaud Bayle, et al.
European Journal of Haematology
|
September 21, 2024
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023
Matteo Guerra, Emily Alouani, Thomas Hueso, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology
Emily Alouani, Ariane Laparra, Audrey Perret, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 22, 2026
Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort
Cedric Pobel, Hassan Badreddine, Cristina Smolenschi, et al.
JCO Precision Oncology
|
May 30, 2024
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial
Julieta Rodriguez, Capucine Baldini, Arnaud Bayle, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
Arthur Géraud, Thomas Hueso, Ariane Laparra, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study
Matthieu Delaye, Paul Matte, Adrien Mouren, et al.
Cell Reports. Medicine
|
February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Stephane Champiat, Elena Garralda, Vladimir Galvao, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Genome Medicine
|
November 4, 2025
Genome instability and crosstalk with the immune response
Roman M Chabanon, François-Xavier Danlos, Kaissa Ouali, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2024
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
Laurent Mathiot, David Combarel, Justin Cagnat, et al.
Cancer
|
June 2, 2024
Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer
Félix Blanc-Durand, Geraldine M Camilleri, Arnaud Bayle, et al.
European Journal of Haematology
|
September 21, 2024
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023
Matteo Guerra, Emily Alouani, Thomas Hueso, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology
Emily Alouani, Ariane Laparra, Audrey Perret, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 22, 2026
Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort
Cedric Pobel, Hassan Badreddine, Cristina Smolenschi, et al.
JCO Precision Oncology
|
May 30, 2024
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial
Julieta Rodriguez, Capucine Baldini, Arnaud Bayle, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
Arthur Géraud, Thomas Hueso, Ariane Laparra, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study
Matthieu Delaye, Paul Matte, Adrien Mouren, et al.
Cell Reports. Medicine
|
February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Stephane Champiat, Elena Garralda, Vladimir Galvao, et al.
Page
of 2